CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 547 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK2-IN-19
CDK2-IN-19 (Compound 32) is a selective, orally active inhibitor of CDK2 (K i: 0.18 nM) that exhibits anticancer activity in mice with OVCAR3 tumors [1].Fórmula:C20H21FN6O4SPureza:98%Cor e Forma:SolidPeso molecular:460.48CDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Fórmula:C22H28ClFN6O4SCor e Forma:SolidPeso molecular:527.01NecroIr1
NecroIr1, an iridium(III) complex, induces necroptosis in Cisplatin-resistant lung cells, targeting mitochondria and disrupting MMP.Fórmula:C40H29ClIrN5OCor e Forma:SolidPeso molecular:823.36CDK7/9-IN-1
CAS:CDK7/9-IN-1 inhibits CDK7/9 with IC50: 0.0656 μM (no pre-incubation), 0.00574 μM (3h pre-inc.), and CDK9: 2.14 μM (3h pre-inc.) for cancer research.Fórmula:C24H32F3N5O2Cor e Forma:SolidPeso molecular:479.548CDK6/9-IN-1
CAS:CDK6/9-IN-1, an oral dual inhibitor of CDK6/9, has IC50s of 40.5nM (CDK6) and 39.5nM (CDK9).Fórmula:C22H25ClN8OCor e Forma:SolidPeso molecular:452.95Anticancer agent 264
Anticanceragent 264 (Compound 5w) is an anticancer compound that exhibits significant antiproliferative activity in tumor cell lines, with an IC50 range of 7.5-33.67 μM. It notably induces cell cycle arrest at the G2/M phase in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. This compound reduces key cell cycle proteins CDK1, CDK2, and Cyclin B1 in a dose-dependent manner and has strong binding activity with differentiation inhibitors and DNA-binding proteins. Anticanceragent 264 is useful for research in the cancer disease domain.Fórmula:C23H18ClF5N6OCor e Forma:SolidPeso molecular:524.87SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Fórmula:C15H14N2OPureza:99.96%Cor e Forma:SolidPeso molecular:238.28PROTAC CDK9 degrader-7
CAS:PROTAC CDK9 degrader-7 is a proteolysis-targeting chimera (PROTAC) specifically designed to target and mediate the degradation of Cyclin-Dependent Kinase 9 (Fórmula:C43H50Cl2N8O9Cor e Forma:SoildPeso molecular:893.81CDK9-IN-27
CDK9-IN-27 (Compound 6a), a CDK9 inhibitor with an IC50 of 0.424 μM, induces apoptosis and S-phase cell cycle arrest.Fórmula:C23H18ClN5O3Pureza:98%Cor e Forma:SolidPeso molecular:447.87JH-XI-10-02
CAS:JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Fórmula:C53H69N5O9Pureza:98%Cor e Forma:SolidPeso molecular:920.161[pThr3]-CDK5 Substrate
CAS:[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM[1].Fórmula:C53H100N15O15PPureza:98%Cor e Forma:SolidPeso molecular:1218.43[pSer2, pSer5, pSer7]-CTD TFA
Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.Fórmula:C98H138F3N21O39Pureza:98%Cor e Forma:SolidPeso molecular:2291.25Ribociclib hydrochloride
CAS:Ribociclib hydrochloride (LEE011 HCl) is a selective, orally active cyclin-dependent kinase CDK4/6 inhibitor (IC50=10/39 nM) that inhibits proliferation.Fórmula:C23H31ClN8OPureza:99.87%Cor e Forma:SolidPeso molecular:471NU6102
CAS:NU6102 is a CDK2 inhibitor with antitumor activity against CDK1/cyclinB, CDK1/CDK2, CDK4, DYRK1A , PDK1, and ROCKII, and it can be used to study rectal cancer.Fórmula:C18H22N6O3SPureza:99.76%Cor e Forma:SolidPeso molecular:402.47LDC4297
CAS:LDC4297 (LDC044297) is a potent and selective CDK7 inhibitor.Fórmula:C23H28N8OPureza:98.25%Cor e Forma:SolidPeso molecular:432.52CDK5-IN-3
CAS:CDK5-IN-3 is a selective and potent CDK5 inhibitor that inhibits CDK5/p25 and CDK2/CycA, and can be used in the study of cancer.Fórmula:C22H26N4OPureza:98.21%Cor e Forma:SolidPeso molecular:362.47Palbociclib-d8
CAS:Palbociclib-d8 (PD 0332991 D8) is the deuterated form of Palbociclib. Palbociclib is a CDK inhibitor that inhibits CDK4 and CDK6.Fórmula:C24H21D8N7O2Pureza:98%Cor e Forma:SolidPeso molecular:455.58PROTAC CDK9 Degrader-1
CAS:PROTAC CDK9 Degrader-1 is a selective PROTAC-based CDK9 degrader, composed of a Cereblon ligand and a CDK ligand.Fórmula:C33H35N5O7Pureza:95.1%Cor e Forma:SolidPeso molecular:613.66TG-693
CAS:TG-693, Oral CLK1 inhibitor, promotes exon 31 skipping of dystrophin gene, inhibits CLK1 substrate phosphorylation, for Duchenne muscular dystrophy.Fórmula:C12H9N3Pureza:99.81%Cor e Forma:SolidPeso molecular:195.23NCT02
CAS:NCT02 degrades cyclin K, leading to CCNK and CDK12 degradation, potentially aiding metastatic CRC research.Fórmula:C17H16N2O2SCor e Forma:SolidPeso molecular:312.39
![[pThr3]-CDK5 Substrate](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FTP1602.webp&w=3840&q=75)
